GID8 Antibody

What is GID8 and why is it important in cellular biology?

GID8 is a 228 amino acid protein (26.7 kDa) localized in the nucleus and cytoplasm and widely expressed across multiple tissue types . As a component of the CTLH E3 ubiquitin-protein ligase complex, GID8 plays a crucial role in protein degradation by mediating ubiquitination. Specifically, the complex selectively accepts ubiquitin from UBE2H and facilitates the ubiquitination and subsequent proteasomal degradation of the transcription factor HBP1 . Recent studies have demonstrated that the GID/CTLH complex contributes to cell cycle regulation, preventing cell cycle exit in G1 phase partly through HBP1 degradation . This positions GID8 as an important regulatory protein in cell proliferation pathways, making it relevant for cancer research, developmental biology, and cellular homeostasis studies.

How do I select the appropriate GID8 antibody for my specific research application?

Selection of an appropriate GID8 antibody depends on several experimental factors:

When selecting between available antibodies, consider: (1) the conservation of your target epitope across species if working with non-human models, (2) whether the antibody has been validated for your specific application with published references, and (3) whether the recognition site might be masked by protein interactions in your experimental conditions . For complex applications like chromatin immunoprecipitation, additional validation steps are recommended.

What are the key differences between polyclonal and monoclonal GID8 antibodies in research applications?

The choice between polyclonal and monoclonal GID8 antibodies depends on your experimental goals:

Monoclonal GID8 antibodies recognize a single epitope with high specificity, offering consistent performance across experiments and reducing background. They are preferred for distinguishing between closely related proteins or specific protein variants. Their consistent production makes them ideal for long-term studies requiring antibody standardization.

What are the optimal experimental conditions for western blot detection of GID8?

For optimal western blot detection of GID8 (26.7 kDa), follow these methodological considerations:

• Sample preparation: Use RIPA buffer with protease inhibitors, with particular attention to inhibitors of the ubiquitin-proteasome pathway since GID8 functions within an E3 ligase complex .

• Gel percentage and transfer conditions:

  • Use 12-15% polyacrylamide gels for optimal resolution of the 26.7 kDa GID8 protein

  • Transfer at 100V for 60-90 minutes using PVDF membranes (0.45 μm) for better protein retention

  • Validate transfer efficiency with reversible staining before blocking

• Blocking and antibody dilutions:

  • Block with 5% non-fat dry milk in TBS-T (preferred over BSA for GID8 detection)

  • Primary antibody dilutions typically range from 1:500 to 1:2000 depending on the specific antibody

  • Overnight incubation at 4°C generally yields better signal-to-noise ratio than shorter room temperature incubations

• Special considerations:

  • Include positive control lysates from tissues known to express GID8 abundantly

  • Given GID8's role in ubiquitination, consider running parallel samples treated with proteasome inhibitors (e.g., MG132) to verify antibody specificity in detecting both free and complex-associated GID8

• Signal detection:

  • Enhanced chemiluminescence (ECL) systems provide sufficient sensitivity for endogenous GID8 detection

  • For challenging samples with low expression, consider fluorescent secondary antibodies for improved quantification capabilities

Researchers should establish a standard curve of recombinant GID8 protein for quantitative applications, as this improves the reliability of comparative analyses across multiple experiments .

How can I optimize immunofluorescence protocols for detecting GID8 in different cell types?

Optimizing immunofluorescence protocols for GID8 requires attention to its dual nuclear and cytoplasmic localization:

When interpreting results, remember that GID8 localization may shift based on cell cycle phase or stress conditions, which should be controlled for in experimental design .

What are effective strategies for using GID8 antibodies in immunoprecipitation experiments?

Effective immunoprecipitation (IP) of GID8 requires special consideration of its role in protein complexes:

• Lysis buffer selection:

  • Standard buffer: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate

  • For preserving CTLH complex interactions: Use milder detergents (0.3% CHAPS or 0.1% digitonin)

  • Always include protease inhibitors and phosphatase inhibitors

• Pre-clearing strategy:

  • Pre-clear lysates with Protein A/G beads for 1 hour at 4°C to reduce non-specific binding

  • For tissues with high lipid content, additional centrifugation steps (16,000g for 10 minutes) before pre-clearing help reduce background

• Antibody binding optimization:

  • Direct approach: Add 2-5 μg antibody per 500 μg lysate protein

  • Indirect approach: Pre-bind antibody to beads before adding to lysate (recommended for detecting GID8 interactions)

  • Incubation time: Minimum 4 hours, optimally overnight at 4°C with gentle rotation

• Co-IP considerations for CTLH complex components:

  • Cross-linking with DSP (dithiobis[succinimidyl propionate]) may help preserve weak or transient interactions

  • For studying GID8-HBP1 interactions, consider reversible cross-linking approaches

  • Sequential IPs can help isolate specific subcomplexes (e.g., first IP with RanBP9 followed by GID8)

• Elution and analysis:

  • Gentle elution with increasing pH (rather than boiling in SDS) can help maintain complex integrity for downstream analysis

  • For mass spectrometry applications, on-bead digestion often yields better results than eluted samples

When analyzing IP results, remember that GID8 functions within the larger CTLH complex, so co-IP of other complex members like RanBP9, MAEA, and TWA1 can serve as positive controls for successful GID8 immunoprecipitation .

How can I address common issues with GID8 antibody specificity and cross-reactivity?

Addressing specificity issues with GID8 antibodies requires systematic troubleshooting:

• Common cross-reactivity issues:

  • GID8 antibodies may cross-react with its paralogues or other LisH/CTLH domain-containing proteins

  • Sequence homology between human GID8 (TWA1) and orthologues in research models may cause unexpected reactivity

• Validation approaches for confirming specificity:

  Validation Method	Technical Approach	Interpretation
  Genetic knockdown	siRNA or CRISPR targeting GID8	Reduction/loss of band/signal at expected MW confirms specificity
  Overexpression	Transfection with tagged GID8 constructs	Additional band at expected MW plus tag size confirms detection
  Peptide competition	Pre-incubate antibody with immunizing peptide	Specific signals should be eliminated or reduced
  Multiple antibodies	Test different antibodies targeting distinct GID8 epitopes	Consistent detection pattern increases confidence

• Technical optimization to reduce non-specific binding:

  • Increase blocking time (2-3 hours) with 5% milk or BSA

  • Include 0.1-0.5% Tween-20 in wash buffers

  • For immunofluorescence, include 10% serum from host species of secondary antibody

  • Use more stringent washing (increased salt concentration up to 500 mM NaCl)

• Methodological approach to distinguishing specific from non-specific signals:

  • Always include molecular weight markers and expect GID8 at approximately 26.7 kDa

  • Be aware that post-translational modifications, particularly ubiquitination, may shift apparent molecular weight

  • For challenging samples, consider orthogonal detection methods (e.g., mass spectrometry) to confirm antibody specificity

When publishing research utilizing GID8 antibodies, researchers should explicitly document the validation methods employed to establish specificity, including catalog numbers and validation data .

What strategies help overcome poor signal-to-noise ratio when detecting GID8 in different experimental contexts?

Optimizing signal-to-noise ratio for GID8 detection requires application-specific strategies:

• Western blotting optimization:

  • Increase antibody concentration incrementally (e.g., from 1:1000 to 1:500)

  • Extend primary antibody incubation to overnight at 4°C

  • Use high-sensitivity detection systems (ECL Prime or femto substrates)

  • Reduce membrane blocking time if signal is too weak

  • Consider signal enhancers specific to your detection system

• Immunohistochemistry/Immunofluorescence improvement:

  • Optimize antigen retrieval methods (test both citrate and EDTA-based buffers)

  • Increase antibody concentration while shortening incubation time to reduce background

  • Use tyramide signal amplification for low-abundance detection

  • Apply Sudan Black B (0.1-0.3%) treatment to reduce autofluorescence

  • Employ confocal microscopy with appropriate negative controls for better signal discrimination

• ELISA detection enhancement:

  • Test different antibody pairs for capture and detection

  • Explore alternative blocking agents (BSA vs. milk vs. commercial blockers)

  • Apply longer substrate development times with careful monitoring

  • Consider overnight sample incubation at 4°C to improve antigen capture

• Special considerations for tissues with high background:

  • For brain tissue: Additional blocking with mouse IgG can reduce non-specific binding

  • For liver tissue: Extended washings and lower antibody concentrations help reduce background

  • For tissues with high endogenous peroxidase: Double quenching with H₂O₂ before antibody application

The principle of progressive optimization—starting with standard conditions and methodically varying one parameter at a time while documenting outcomes—remains the most reliable approach to improving signal-to-noise ratio for GID8 detection .

How should researchers interpret discrepancies in GID8 detection between different antibodies or techniques?

Interpreting discrepancies in GID8 detection requires systematic analysis:

• Common discrepancy patterns and likely causes:

  Discrepancy Type	Possible Explanations	Resolution Approach
  Different MW bands	Post-translational modifications, splice variants, degradation products	Western blot with denaturing/reducing conditions; phosphatase/deubiquitinase treatment
  Inconsistent subcellular localization	Epitope masking in complexes, cell-type specific interactions, fixation artifacts	Compare multiple fixation protocols; validate with fractionation studies
  Presence/absence in specific tissues	Expression level differences, epitope accessibility	qPCR validation; use multiple antibodies targeting different epitopes

• Methodological approach to resolving discrepancies:

  • Perform side-by-side comparisons under identical experimental conditions

  • Validate with orthogonal techniques (e.g., mass spectrometry, RNA-seq)

  • Consider epitope mapping to understand which protein regions each antibody recognizes

  • Test under different cellular conditions (stress, cell cycle phases) as GID8's interactions may be context-dependent

• Interpretation framework:

  • Consider that different antibodies may preferentially detect free GID8 vs. complex-bound GID8

  • Remember that GID8's dual nuclear/cytoplasmic localization may show different patterns depending on experimental conditions

  • Evaluate whether discrepancies correlate with detection of other CTLH complex components

• Documentation and reporting standards:

  • Record lot numbers, dilutions, and detailed protocols

  • Document all observed discrepancies systematically

  • Consider collaborative validation when critical findings depend on antibody specificity

When facing persistent discrepancies, utilizing genetic approaches (CRISPR knockout followed by reconstitution) provides the strongest validation of antibody specificity and can help resolve contradictory observations .

How can GID8 antibodies be employed to study the dynamics of CTLH E3 ubiquitin ligase complex assembly?

GID8 antibodies provide powerful tools for investigating CTLH complex dynamics through several sophisticated approaches:

• Sequential immunoprecipitation methodology:

  • First IP: Use antibodies against RanBP9 (Gid1) to pull down the entire CTLH complex

  • Elution: Gentle elution with competing peptide rather than denaturing conditions

  • Second IP: Use GID8 antibodies to isolate specific sub-complexes

  • Analysis: Mass spectrometry to identify differential complex composition

• Proximity-based labeling coupled with immunodetection:

  • Express BioID or APEX2 fusions with GID8 or other CTLH components

  • Perform proximity labeling followed by streptavidin pulldown

  • Use GID8 antibodies to quantify the fraction of GID8 in proximity to different complex members

  • This approach reveals spatial relationships within the complex architecture

• Cross-linking mass spectrometry workflow:

  • Apply membrane-permeable cross-linkers to intact cells

  • Immunoprecipitate with GID8 antibodies

  • Perform LC-MS/MS analysis of cross-linked peptides

  • Map interaction interfaces between GID8 and other CTLH components

• Antibody-based tracking of complex assembly kinetics:

  • Synchronize cells and collect time-course samples

  • Perform co-IP with GID8 antibodies at different time points

  • Western blot for other complex members (RanBP9, MAEA, WDR26, etc.)

  • Quantify the differential assembly rates and stoichiometry

• Single-molecule approaches:

  • Use directly labeled GID8 antibodies for super-resolution microscopy

  • Employ split-GFP complementation combined with GID8 immunofluorescence

  • These approaches provide spatial and temporal resolution of complex formation

Recent research has shown that individual CTLH complexes may contain either Rmnd5a or Rmnd5b (but not both), suggesting mutually exclusive subunit incorporation . GID8 antibodies can help determine whether these different complex variants have distinct cellular localizations or functions through careful co-localization studies.

What approaches enable using GID8 antibodies to investigate the role of this protein in cell cycle regulation and cancer biology?

GID8 antibodies enable sophisticated investigations of its role in cell cycle regulation and cancer through these methodological approaches:

• Cell cycle phase-specific analysis:

  • Synchronize cells at different cell cycle phases (G1, S, G2/M)

  • Immunoprecipitate GID8 from each phase

  • Analyze interactome changes across the cell cycle via mass spectrometry

  • Parallel western blot analysis for cell cycle regulators that might be GID8/CTLH substrates

• HBP1 degradation pathway analysis:

  • Treat cells with proteasome inhibitors (MG132, bortezomib)

  • Perform co-IP with GID8 antibodies

  • Blot for HBP1 and ubiquitin to capture intermediates in the degradation pathway

  • Use cycloheximide chase experiments with GID8 antibody detection to measure HBP1 half-life

• Cancer tissue microarray analysis:

  • Perform immunohistochemistry with GID8 antibodies across cancer types

  • Quantify expression levels and subcellular localization patterns

  • Correlate with proliferation markers (Ki-67) and patient outcome data

  • Compare primary tumors vs. metastases to assess expression changes during progression

• Functional studies in cancer cell models:

  • Create GID8 knockdown and overexpression cell lines

  • Perform rescue experiments with GID8 mutants defective in CTLH complex integration

  • Use GID8 antibodies to validate expression levels and complex formation

  • Assess effects on cell cycle progression, migration, and invasion

• Advanced imaging applications:

  • Employ live-cell imaging with fluorescently tagged GID8 combined with fixed-cell antibody validation

  • Perform FRAP (Fluorescence Recovery After Photobleaching) to assess GID8 mobility during cell cycle

  • Use proximity ligation assays (PLA) to visualize GID8-HBP1 interactions in situ

Given that the GID/CTLH complex prevents cell cycle exit in G1 phase partly through HBP1 degradation , systematic analysis of GID8 expression and interaction patterns across cancer types may reveal novel therapeutic vulnerabilities, particularly in cancers dependent on dysregulated G1/S transition.

How can mass spectrometry be integrated with GID8 antibody-based approaches to identify novel interaction partners and substrates?

Integrating mass spectrometry with GID8 antibody techniques enables powerful substrate discovery through these methodological approaches:

• Antibody-based BioID proximity labeling:

  • Fuse BioID or TurboID to GID8

  • Validate expression and functionality using GID8 antibodies

  • After biotin labeling, purify biotinylated proteins

  • Identify proximal proteins by mass spectrometry

  • Validate key candidates with reciprocal co-IP using GID8 antibodies

• SILAC-based quantitative interaction proteomics:

  Condition	SILAC Label	Experimental Setup
  Control	Light (K0R0)	Normal conditions
  Experimental	Heavy (K8R10)	Proteasome inhibition
  Validation	Medium (K4R6)	GID8 knockdown

  • Immunoprecipitate with GID8 antibodies from mixed lysates

  • Identify enriched proteins by LC-MS/MS

  • Quantify relative abundance across conditions

  • Potential substrates will show enrichment in heavy (proteasome inhibited) condition

• Ubiquitinome analysis pipeline:

  • Treat cells with proteasome inhibitors ± GID8 knockdown

  • Enrich for ubiquitinated proteins using tandem ubiquitin binding entities (TUBEs)

  • Perform parallel GID8 immunoprecipitation

  • Compare ubiquitinome changes between conditions by mass spectrometry

  • Validate candidates showing reduced ubiquitination upon GID8 depletion

• In vitro reconstitution coupled with mass spectrometry:

  • Immunopurify intact CTLH complex using GID8 antibodies

  • Perform in vitro ubiquitination assays with candidate substrates or cell lysates

  • Identify ubiquitinated proteins by mass spectrometry

  • Confirm with recombinant proteins and site-directed mutagenesis

• Crosslinking mass spectrometry for structural insights:

  • Apply protein crosslinkers to intact cells or purified complexes

  • Immunoprecipitate GID8-containing complexes

  • Identify crosslinked peptides by specialized mass spectrometry

  • Map interaction interfaces and complex architecture

These approaches have revealed that beyond HBP1, the GID/CTLH complex may target additional substrates involved in metabolic regulation and cell cycle control . Integration of antibody-based enrichment with mass spectrometry provides the necessary sensitivity to detect transient interactions between E3 ligase complexes and their substrates.

How might emerging antibody technologies enhance GID8 research beyond conventional applications?

Emerging antibody technologies offer transformative potential for GID8 research:

• Single-domain antibodies (nanobodies) development:

  • Nanobodies against GID8 could access epitopes inaccessible to conventional antibodies

  • Their small size (15 kDa vs. 150 kDa) enables superior tissue penetration and reduced steric hindrance

  • Can be expressed intracellularly as "intrabodies" to track or perturb GID8 function in live cells

  • Recent advances in de novo nanobody design through RFdiffusion networks may accelerate development of GID8-specific nanobodies

• Proximity-dependent antibody platforms:

  • Split-enzyme complementation (NanoBiT, HiBiT) fused to anti-GID8 antibody fragments

  • Antibody-based FRET sensors to detect GID8-substrate interactions in real-time

  • Photocrosslinking antibodies that covalently capture transient GID8 interactions upon light activation

• Degradation-inducing antibody technologies:

  • PROTAC-conjugated antibodies targeting GID8 for inducible degradation

  • Lysosome-targeting chimeras (LYTACs) for GID8 depletion in therapy-resistant contexts

  • These approaches enable acute depletion experiments to assess temporal requirements for GID8

• Spatially-resolved antibody applications:

  • Expansion microscopy compatible GID8 antibodies for super-resolution imaging

  • Antibody-based spatial transcriptomics to correlate GID8 protein localization with local mRNA expression

  • Tissue clearing techniques combined with whole-mount GID8 immunolabeling

• Machine learning integration:

  • Active learning algorithms to predict GID8-substrate interactions based on antibody-derived training data

  • Computational approaches can reduce the experimental burden by prioritizing the most promising candidate interactions

  • Deep learning models to predict epitope accessibility in different cellular contexts

This technological convergence will enable researchers to move beyond static snapshots of GID8 function toward dynamic, spatiotemporally resolved understanding of its roles in ubiquitination and cell cycle regulation .

What are the most promising approaches for studying GID8 post-translational modifications using antibody-based detection?

Studying GID8 post-translational modifications (PTMs) requires specialized antibody-based approaches:

• Phosphorylation analysis workflow:

  • Immunoprecipitate GID8 under phosphatase inhibitor protection

  • Perform western blot with phospho-specific antibodies targeting predicted sites

  • For comprehensive analysis, employ phospho-enrichment followed by mass spectrometry

  • Validate key sites with phospho-mimetic and phospho-dead GID8 mutants

• Ubiquitination detection strategies:

  Approach	Methodology	Advantages
  K-ε-GG antibodies	Enrich ubiquitinated peptides after trypsin digestion	Site-specific identification
  UbiSite technology	Combines chemical crosslinking with K-ε-GG enrichment	Enhanced sensitivity
  TUBEs pulldown	Tandem ubiquitin-binding entities followed by GID8 antibody detection	Preserves native complexes

• SUMOylation and other UBL modifications:

  • Express epitope-tagged SUMO in cells

  • Perform denaturing IP to enrich SUMOylated proteins

  • Blot with GID8 antibodies to detect modified forms

  • Validate with SUMO-site prediction algorithms and mutagenesis

• PTM crosstalk analysis:

  • Sequential immunoprecipitation with PTM-specific antibodies followed by GID8 detection

  • Alternatively, first IP with GID8 antibodies followed by PTM-specific antibody detection

  • Time-course analysis after stimulation to track modification dynamics

  • Inhibitor studies to establish modification hierarchies

• Functional validation of PTMs:

  • Generate site-specific antibodies against key GID8 PTM sites

  • Use these for quantitative monitoring during cell cycle progression or stress response

  • Correlate modifications with changes in CTLH complex assembly or activity

  • Perform rescue experiments with modification-mimetic mutants

These approaches can reveal how PTMs regulate GID8's incorporation into the CTLH complex, its subcellular localization, or its substrate recognition properties—aspects currently underexplored but potentially critical for understanding the contextual regulation of this E3 ligase component.

How can GID8 antibodies contribute to understanding evolutionary conservation and divergence of the CTLH complex across species?

GID8 antibodies enable comparative evolutionary studies through these methodological approaches:

• Cross-species reactivity analysis:

  • Test existing GID8 antibodies against lysates from diverse organisms

  • Perform epitope mapping to identify conserved recognition regions

  • Generate new antibodies targeting evolutionarily conserved epitopes

  • Use these tools to compare expression patterns across model organisms

• Comparative immunoprecipitation studies:

  • Perform GID8 immunoprecipitation from lysates of diverse species

  • Analyze co-precipitating proteins by mass spectrometry

  • Compare complex composition across evolutionary distance

  • Identify species-specific interactors that may represent functional adaptations

• Structural conservation assessment:

  Species	Sequence Identity (%)	Complex Components	Functional Divergence
  Human	100 (reference)	Complete CTLH complex	Cell cycle regulation via HBP1
  Mouse	~90	Similar to human	To be determined with antibody studies
  Yeast	~30 (GID8)	GID complex	Gluconeogenic enzyme degradation
  Others	Variable	To be determined	Active research area

• Tissue and developmental expression mapping:

  • Use validated GID8 antibodies for immunohistochemistry across species

  • Compare expression patterns during embryonic development

  • Identify conserved vs. divergent expression domains

  • Correlate with tissue-specific functions through co-expression analysis

• Functional complementation approaches:

  • Express GID8 orthologues from different species in human cells

  • Use antibodies to verify expression and complex incorporation

  • Assess functional rescue of GID8 knockout phenotypes

  • Identify critical regions through domain swapping experiments

These comparative approaches can reveal how the CTLH complex evolved from its ancestral role in metabolic regulation in yeast (where it targets gluconeogenic enzymes) to additional functions in cell cycle control in mammals (where it targets HBP1) . Understanding this evolutionary trajectory may uncover fundamental principles about the adaptation of E3 ubiquitin ligase complexes to new cellular functions.

How can researchers integrate multiple antibody-based techniques to build a comprehensive understanding of GID8 biology?

Integrating multiple antibody-based approaches creates a comprehensive framework for understanding GID8 biology:

• Multi-modal workflow integration:

  • Begin with expression profiling using validated GID8 antibodies across tissues and cell types

  • Follow with subcellular localization studies using immunofluorescence and fractionation

  • Perform interaction mapping through co-IP and proximity labeling

  • Investigate dynamic changes under various cellular conditions or perturbations

  • This stepwise approach builds from descriptive to mechanistic understanding

• Cross-validation strategy:

  • Use orthogonal antibody-based techniques to verify key findings

  • Complement antibody approaches with genetic tools (CRISPR, RNAi)

  • Integrate data from antibody studies with genomic, transcriptomic and proteomic datasets

  • Apply mathematical modeling to predict system-level behaviors based on antibody-derived data

• Technological synergy exploitation:

  Primary Technique	Complementary Approach	Resulting Insight
  Western blot	Mass spectrometry	Protein abundance and modification state
  Immunofluorescence	Live-cell imaging	Static localization and dynamic behavior
  Immunoprecipitation	Proximity labeling	Stable interactions and transient associations
  ChIP-seq	CUT&RUN with GID8 antibodies	Genomic associations and regulatory functions

• Temporal and contextual framework development:

  • Track GID8 expression, localization, and interactions across cell cycle

  • Map responses to cellular stresses, metabolic shifts, and signaling events

  • Create condition-specific interaction networks centered on GID8

  • Identify context-dependent regulatory mechanisms

• Translational connection establishment:

  • Correlate GID8 expression/modification patterns with disease states

  • Develop tissue microarray studies using optimized GID8 antibodies

  • Connect basic mechanistic insights to potential therapeutic approaches

  • Consider GID8/CTLH complex as a therapeutic target based on integrated knowledge